Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Crucell Channelwww.youtube.com/user/CrucellVideo Working at Crucell At Crucell we dream of a world free of infectious disease. In 2010, our vaccines prevented more than 3.6 million cases of infectious disease and over 809,000 deaths. Are you looking for a job where you can make a real difference to global health? Come and join us!www.crucell.com/Careers www.youtube.com/watch?v=DkJPy96QhkE Crucell corporate moviewww.youtube.com/watch?v=_vq-0K75_qg ************ BIT Life Sciences 3rd Annual World Vaccine Eventwww.bitlifesciences.com/wcv2011/defau... Bejing CN Crucell's CSO, Dr Jaap Goudsmit will give a presentation entitled "Protective Immunity of vaccine efficacy: Lessons learned from West Nile" 12 april 2011 15:40 () World Congress Vaccine Washington 2011, Crucell sponsored eventwww.terrapinn.com/conference/world-va... Washington, DC US Crucell's VP for Preclinical and Clinical Research, Dr Robert Friesen will give a presentation entitled: Novel human monclonal antibodies against group 1 and 2 Influenza A strains for prevention and treatment 8 mei 2011 12:53 () International Society of Travel Medicine, Crucell sponsored eventwww.istm.org/ Boston US From 08-12 May 2011 7 juni 2011 12:53 () 29th Annual meeting for the European Society for Pediatric Infectious Disease, ESPIDwww2.kenes.com/espid2011/Pages/Home.aspx Hague NL From 7-11 June 2011, off site Crucell sponsored event *********** A peptide based Plasmodium falciparum circumsporozoite assay to test for serum antibody responses to pre-erythrocyte malaria vaccines.www.ncbi.nlm.nih.gov/pubmed/21411600 Successful Memory Response Following an up to 11 Years Delayed Booster Dose with a Virosome-formulated Hepatitis A Vaccine (Epaxal(R)).www.ncbi.nlm.nih.gov/pubmed/21411599 ********** Crucell ’s(a subsidiary of Johnson & Johnson) PER.C6 inside: PAT-SM6 Disease Target, GRP78, Gains Growing Attention from Research Community www.patrys.com/images/stories/mediare... Gastric Cancer Antibody Exceeds Manufacturing Yield Expectations; Disease Target of Industry Interestwww.patrys.com/images/stories/mediare... PATRYS PRESENTS TO INVESTORS IN AUSTRALIA AND ASIAwww.patrys.com/images/stories/mediare... ********* Antwoord vragen Gesthuizen over persoonlijk belang commissarissen bij overname Crucell. ikregeer.nl/s/ah-103046 ******** Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccinesclinicaltrials.gov/ct2/show/NCT013074... clinicaltrials.gov/ct2/results?term=C... ************www.youtube.com/watch?v=PTTsyk-pyd8 Btw: Tomorrow is WorldTBDay!
Adimmune to Kick Off Human-Vaccine Exports This Year Taipei, March 31, 2011 (CENS)--Adimmune Corp., the only cGMP (current Good Manufacturing Practices) human-vaccine maker in Taiwan, recently claimed that it will begin exporting human vaccines this year and tap the European Union (EU) market in partnership with Netherlands-based biotechnology company Crucell N.V. Adimmune estimates that its exports will account for about 10% of revenue this year, but are expected to rise to more than 70% in three to five years. The Taiwanese vaccine maker is capitalized at NT$1.64 billion (US$54.6 million), and its major products include vaccines for influenzas (accounting about 70% of the firm`s overall revenue), Japanese encephalitis (20%), and tetanus (10%). Adimmune registered revenue of NT$840 million (US$28 million) in 2010, or pretax earnings of NT$225 million (US$7.5 million) and pretax earnings per share (EPS) of NT$1.37 (US$0.05). COMPANY STEVE CHAN SAID THAT HIS COMPANY HAD SIGNED A SEVEN-YEAR AGREEMENT WITH CRUCELL TO SUPPLY THE ORIGINAL AGENT TO THE NETHERLANDS-BASED PARTNER, ADDING THAT HE ALSO HOPES ADIMUNNE CAN DIVERSIFY ITS LINE TO INCLUDE VACCINES. ACCORDING TO CHAN, CRUCELL OWNS THE LICENSES FOR VENDING INFLUENZA DRUGS IN 45 NATIONS, SO IS A GOOD PARTNER TO EXPAND ADIMMUNE`S GLOBAL SALES. ADIMMUNE`S INFLUENZA VACCINE IS APPLYING FOR NEW-DRUG LICENSES TO SWISS AND EU, AFTER COMPLETED CLINICAL TESTS IN SWISS. Chan claimed that several new vaccines are under development at Adimmune, including that for bird flu (H5N1 virus), intestine virus (EV71) etc. The bird-flu vaccine is fully homegrown, which can only be made in 30 plants in 18 nations.news.cens.com/cens/html/en/news/news_...
een goed bericht, maar voor ons te laat... heb nog steeds geen echte vervanger voor crucell gevonden.. wel wat gestopt in galapagos en morphosys rest buiten de biotech.
Sinds 2005 was Crucell een slechte investering, zeker in het licht van de verwachtingen die gewekt zijn in al die jaren. Het beste was geweest , in retrospect, afscheid te nemen in 2005 , en dan zou je porto met een faktor 10 gestegen zijn. Want sinds ik afscheid heb genomen is mijn porto in minder dan 1 jaar met vele honderden procenten gestegen. Dus 5 jaar zou zeker 1000% geworden zijn. Niet in de Biotech, maar in vele andere aandelen die je geen worst voorhouden. Voor mij nooit geen AVA meer en nooit geen Biotech. Het liedje : ik ben belazerd is hierop van toepassing van onze Limburger uit de oude doos.Wim Sonneveld voor de nietwetenden Nooit geen AVA meer, met 1 uitzondering: Als mijn investering ( nu 10 keer over de kop) naar 100 keer over de kop gaat. (:->) Maar ik zal nooit vergeten : Geen woorden maar daden.
AVA kan voortaan beter AVM heten: Algemene Vergadering van Misleidenen. Ook sterkte met het verwerken van deze ervaring, wilb; ikzelf ben nog slechts een beetje in de rouwfase; verder gaat het wel weer...
Graphic on the vaccine market graphics.thomsonreuters.com/F/09/US_V... Nederlandse beleggers kunnen maandag voor het laatst handelen in aandelen Crucell. Het biotechnologiebedrijf is ingelijfd door het Amerikaanse Johnson & Johnson en verdwijnt van de Nederlandse beurs. www.businesscompleet.nl/kennisbank/Ko... www.youtube.com/watch?v=TqhOVY58zIo Fijne kerst…….
Lijkt meer op een treurige oudejaarsavond...
Al bij al toch een mooie pensioenuitkering op de bank dank zij de crucellen... maar wat ermee aan te vangen, IceSave indachtig ? NB. GS waarschuwt voor grondstoffen dip! Weet je wat, ik stop het gewoon in een roze plastic spaarvarkentje omwikkeld in geölied bruin papier en onder de grond ermee!
En dan niet meer weten, waar je dat gat in de bodem hebt gegraven. Over 20 eeuwen komt iemand dat spulletje tegen en vraagt zich af wat voor zootje ongeregeld dat is. Zou die uitgestorven soort iets van ruilhandelondersteuning gedaan hebben?
Hou de coördinaten bij via GPS ;-) En via testament maak ik er een spelletje 'vossenjacht' van...
Weldon: in 2010 JNJ invested nearly $7 billion in R&D #JNJASM, $JNJtwitter.com/#!/JNJComm Here we go - Q&A at J&J's Annual Shareholder Meeting. Weldon asking people to not ask Q's about anything important. #JNJASM #JNJtwitter.com/#!/PharmAid
Now available: Crucell's Corporate Brochure Monday, May 2nd 2011tinyurl.com/6g5crxo Btw: UK nationals overseas urged to be vigilant and monitor media, OBL. ow.ly/4KZZE
...a Crucell vaccine was given to 190 individuals every minute during 2010....www.youtube.com/watch?v=fULgsiJs5TA
Ja Flosz, Wrijf het er nog maar eens in. Gisteren bij AMT op de AVA geweest. Maar een heel klein clubje en zeer bescheiden presentaties. Dat biedt mogelijk meer perspectief voor de toekomst. YinX was er ook en we hebben samen nog maar eens bevestigd dat we ons genaaid voelen door Crucell. Op 19 mei Company visit bij AMT vanaf 15.30 - 18.00 (meer nieuws volgt) Gr Frank
Frenky_Tornado schreef:
Wrijf het er nog maar eens in.
Bioceros Announces Expansion of the Research License Agreement with Crucell on STAR® Technology Utrecht, The Netherlands, 2 May 2011 – Bioceros B.V. today announced the extension of the non-exclusive STAR® research license agreement with Crucell. The license agreement with the Netherlands based company Bioceros covers the production of monoclonal antibodies. In addition, the extension of the agreement now includes the right for Bioceros B.V. to sub-license and independently market the STAR® technology to third parties. Financial details of the agreement were not disclosed. Bioceros’ CEO Dr. Bram Bout comments: “We are proud to add the STAR® technology to our service portfolio, building an even stronger and solid service business for pre-clinical development of biopharmaceutical proteins. The STAR® technology protocols that were developed at the Bioceros facilities on our CHO platforms add significant value to cell line generation procedures as we know it. We also value the continuous confidence that Crucell expresses in the service quality Bioceros delivers by granting Bioceros the right to outlicense the STAR® technology to potential partners of Bioceros.”tinyurl.com/3ngvk9k
Ja, ja, nu werkt het ineens wel weer prachtig ;( Groeten, Frank
Frenky_Tornado schreef:
Op 19 mei Company visit bij AMT vanaf 15.30 - 18.00 (meer nieuws volgt)
May 19: Company Visit to AMT May 6, 2011 Uitnodiging company visit AMT Graag nodigen wij u uit voor onze company visit op 19 mei a.s. van 15:30 – 18:00 uur bij AMT aan de Meibergdreef 61 te Amsterdam. Tijdens deze middag zullen Jörn Aldag (CEO), Piers Morgan (CFO) en Dr. Harald Petry (Director Research) een korte presentatie geven. Aansluitend op deze presentaties volgt een rondleiding door het gebouw van AMT en is er nog ruime gelegenheid om elkaar te spreken tijdens een borrel. U kunt zich voor deze middag aanmelden door een e-mail te sturen naar f.vaneerdenburg@amtbiopharma.com . Er zijn voor deze middag maximaal 30 plaatsen beschikbaar. Indien u bij deze meeting aanwezig wilt zijn is het dus noodzakelijk uzelf tijdig in te schrijven. Voor vragen of meer informatie kunt u contact opnemen met Frank van Eerdenburg via eerder genoemd e-mailadres of telefoonnummer 020 - 556 73 94.www.amtbiopharma.com/finance/news Gr.
CORRECTIE TELEFOONNUMMER In de uitnodiging is een verkeerd telefoonnummer gezet. Dit moet zijn 020 - 5667394 Sorry voor het ongemak
June relaunch for national program Pentavalent Vaccine 12 May, 2011 - The pentavalent vaccine, suspended 18 months ago after five cases of serious ‘adverse effect following immunisation’ (AEFI) or deaths were reported, will be reintroduced next month into the national vaccination programme. Relying on the findings by experts from the World Health Organisation and laboratory tests, public health officials said it was “unlikely” that the five in one vaccine caused the deaths of the nine babies, who had received the vaccine, when it was launched nationwide in October 2009. The vaccine is a combination of vaccines against diphtheria, whooping cough (pertussis), tetanus, hepatitis-B and the haemophilus influenza type B (Hib) germ. It’s given to babies in three doses, when they are six, ten and 14 weeks old. “The deaths were coincidental and, especially in Bhutan, which has an immunisation coverage above 95 percent, any child that falls sick or dies would have had received one vaccine or the other,” public health director, Dr Ugen Dophu said at a press briefing yesterday in Thimphu. A media guide on the vaccine was launched and distributed yesterday. According to health officials 17 hospitals across the country reported two encephalitis, three convulsions, seven meningitis deaths and another seven sudden deaths after the vaccine was suspended. “This indicates that there were deaths even among children, who did not receive the pentavalent vaccine,” the media guide states. There were about 40 cases of encephalitis cases reported last year in children below a year. Given the various causes of meningo-encephalitis, such as bacterial, fungal, viral, chemical and because its associated with other diseases, Dr Ugen Dophu said the ministry cannot guarantee that similar “coincidental deaths” will not occur again. “What we can say is that if we don’t introduce the haemophilus influenza type B (Hib) vaccine into our vaccination program, more than 200 children will continue to die from pneumonia or meningo-encephalitis,” the public health director said. “That’s the rationale to reintroduce the vaccine.” While the vaccine would not eliminate totally the number of children suffering from meningo-encephalitis, it would reduce it, he said. “We can also guarantee the vaccine we bring from the factory to the outreach clinic is brought at the temperature of 2-8 degrees centigrade, and that this would be maintained until it’s injected into our children,” he said. The ministry also guarantees that its health workers would give the vaccine properly and also monitor all children who are given the vaccine. “If the AEFIs reported are due to the vaccine, we’ll accept because it’s about our credibility,” the public health director said. Chief program officer with the public health department Tandin Dorji said data collected between 2006-10 from the region showed that the cases of encephalitis peaked between June and October. “At the time when Bhutan had introduced the vaccine, the whole of south east Asia region was seeing an outbreak of meningo-encephalitis,” he said. “The cases Bhutan had in 2009 suggest a low level of the disease’s outbreak.” The ministry is planning to reintroduce the vaccine on June 11 and is now waiting for the vaccines to reach Bhutan by May 23. Manufactured in South Korea, the vaccine, with a trade name Quinvazem, is produced by Crucell and Novartis companies. An Indian company called Panacea Biotec ltd in New Delhi manufactured the previous vaccine. The ministry is a year into studying the burden of meningo-encephalitis. “It’s a complicated disease, where the cerebro spinal fluid needs to be tested to determine the real cause,” Dr Ugen Dophu said. “If that is found, it can be treated but some deaths do occur.”tinyurl.com/6xqxhg5
Pharmaceuticals Business Review : Infectious Diseases and Vaccines PLANNED FILINGS 2011-2015 FlumAb Rabies Antibody FluCelltinyurl.com/3uchrl8 www.investor.jnj.com/webcasts-present... J&J plans to submit some experimental vaccines for approval. tinyurl.com/3lbuzhz
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
910,59
+0,71%
EUR/USD
1,0771
-0,10%
FTSE 100
8.433,76
+0,63%
Germany40^
18.773,50
+0,47%
Gold spot
2.360,72
0,00%
NY-Nasdaq Composite
16.340,87
-0,03%
Stijgers
Dalers